Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03823300) enrolled 331 people in the faricimab group and 327 people in the aflibercept group — a total of 658 participants. Both faricimab and aflibercept are medicines given by injection into the eye and are used for a type of vision problem affecting the retina (the light-sensitive layer at the back of the eye). The trial's main goal was to measure changes in participants' best corrected visual acuity — that is, the sharpest vision a person can achieve with glasses or contact lenses — over the course of the study, using a standard eye chart scored from 0 to 100 letters (higher is better). The reported data shows that for the primary measure — the average change in vision score from the start of the trial to around weeks 40, 44, and 48 — both groups gained the same number of letters on the eye chart: 6.6 letters in the faricimab group and 6.6 letters in the aflibercept group. For a later time window (weeks 52, 56, and 60), the reported figures were 6.6 letters for faricimab and 7.1 letters for aflibercept. Looking at the proportion of participants who gained 15 or more letters (a commonly used threshold in eye research) averaged over weeks 40–48, the reported data shows approximately 20.2% in the faricimab group and 22.2% in the aflibercept group met this mark; over weeks 52–60, those figures were 22.6% and 23.7% respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 38382813) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Macular Degeneration Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a specific type of wet age-related macular degeneration (AMD) in the eye being studied, and you have not yet received any treatment for it
- You are able and willing to follow all the rules and requirements of the study, as judged by the study doctor
- If you are a woman who could become pregnant, you agree to either not have heterosexual sex or to use a highly effective form of birth control (with less than 1% chance of failure per year) during the treatment and for at least 3 months after the last dose
- There may be additional requirements not listed here (confirm with trial site)
Who may not be able to join:
- Your blood pressure is very high (top number above 180 or bottom number above 100) while resting on the first day of the study
- You are currently pregnant, breastfeeding, or planning to become pregnant during the study
- The eye condition being treated is caused by something other than AMD
- You have a history of other eye problems unrelated to AMD that affect your vision or cause fluid build-up in the study eye
- You have another eye condition in the study eye that could prevent vision improvement or need treatment during the study, in the doctor's opinion
- You have uncontrolled glaucoma in the study eye
- You have previously had any treatment for the eye condition being studied
- You have ever received an eye injection of a drug called faricimab in either eye
- You have a history of a type of eye inflammation called uveitis in either eye
- You currently have active eye inflammation or a suspected or active eye infection in either eye
- There may be additional reasons that could prevent you from joining (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
9 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.